Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: Identification of patients needing therapy

Blood Cancer Journal

Volumn 5, Issue 10, 2015, Pages

  Siontis, B ^a   Kumar, S ^a   Dispenzieri, A ^a   Drake, M T ^a   Lacy, M Q ^a   Buadi, F ^a   Dingli, D ^a   Kapoor, P ^a   Gonsalves, W ^a   Gertz, M A ^a   Rajkumar, S V ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL DECISION MAKING; CLINICAL EVALUATION; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE COURSE; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELOPROLIFERATIVE DISORDER; OSTEOLYSIS; OVERALL SURVIVAL; PROBABILITY; SMOLDERING MULTIPLE MYELOMA; SURVIVAL RATE; MIDDLE AGED; MORTALITY; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; SURVIVAL ANALYSIS; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; MULTIPLE MYELOMA; POSITRON-EMISSION TOMOGRAPHY; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84989315120     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.87     Document Type: Article

References (15)

1. Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood 2015; 125: 3069-3075.
2. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007; 356: 2582-2590.
3. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V et al. International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. Lancet Oncol 2014; 15: e538-e548.
4. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24: 1121-1127.
5. Mateos MV, San Miguel JF Treatment for high-risk smoldering myeloma. N Engl J Med 2013; 369: 1764-1765.
6. Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007; 110: 2586-2592.
7. Kyle RA, Durie BGM, Rajkumar SV, Landgren O, Blade J, Merlini G et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24: 1121-1127.
8. Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 2013; 27: 941-946.
9. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2007; 111: 785-789.
10. Bianchi G, Kyle RA, Larson DR, Witzig TE, Kumar S, Dispenzieri A et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia 2013; 27: 680-685.
11. Hillengass J, Fechtner K, Weber MA, Bauerle T, Ayyaz S, Heiss C et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 2010; 28: 1606-1610.
12. Merz M, Hielscher T, Wagner B, Sauer S, Shah S, Raab MS et al. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. Leukemia 2014; 28: 1902-1908.
13. Rajkumar SV, Merlini G, San Miguel JF Redefining myeloma. Nat Rev Clin Oncol 2012; 9: 494-496.
14. Regelink JC, Minnema MC, Terpos E, Kamphuis MH, Raijmakers PG, Pieters-van den Bos IC et al. Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Br J Haematol 2013; 162: 50-61.
15. Zamagni E, Nanni C, Gay F, Pezzi A, Bellò M, Rambaldi R et al. The presence of FDG PET/CT focal, not osteolytic, lesion(s) identifies a sub-group of patients with smoldering multiple myeloma with high-risk of progression into symptomatic disease. Blood (ASH Annual Meeting Abstract) 2014; 124: A3371.